The Importance of CAPHRA at GoodCOP 2.0
The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) successfully celebrated Asia Day at the GoodCOP 2.0 in Geneva. This significant event coincided with a week dedicated to the global conversation around tobacco control, particularly during the FCTC COP11 discussions. Consumer advocates, public health professionals, medical personnel, and policymakers convened, emphasizing the critical demand for sensible regulation of reduced-risk products.
Unveiling the White Paper: A Call to Action
At this event, CAPHRA introduced a crucial white paper titled Harm Reduction Denied in Asia Pacific. This document sheds light on the inconsistencies in the World Health Organization's (WHO) tobacco control strategies. It advocates for immediate reforms concerning harm reduction within the Framework Convention on Tobacco Control (FCTC). By analyzing WHO's tobacco policies within the SEARO and WPRO regions, this paper presents a fact-based critique, supported by official WHO data. This research leverages insights from reports like the Global Report on Trends in Tobacco Use 2000–2030 and the Global Health Observatory, pinpointing contradictions that require attention.
Key Recommendations for Policymakers
The white paper makes a strong appeal to WHO member states convening at COP11 to reaffirm the principles expressed in Article 1(d) of the FCTC. This involves formally recognizing harm reduction as an essential component of tobacco control. It suggests prioritizing regulation over outright prohibition of safer nicotine products. Additionally, it encourages active participation of affected stakeholders, which includes consumers and independent researchers, in dialogue about policy-making. Transparency and accountability in FCTC processes are also highlighted, advocating for open access to media and equitable representation.
Addressing Public Health Concerns
The report concludes by asserting that the ongoing rejection of tobacco harm reduction not only fails to mitigate preventable diseases, but it also fosters illicit trade and diminishes public trust in health initiatives. The paper urges policymakers to transcend prevailing ideologies and adopt innovative approaches that prioritize the well-being of lives affected by tobacco.
Contact Information for Further Inquiries
If you would like more details about the white paper or wish to discuss its implications, feel free to reach out to: N E Loucas, Executive Coordinator
Email: neloucas@caphraorg.net
WhatsApp: +64 027 234 8463
Website: www.caphraorg.net
Frequently Asked Questions
What is the significance of CAPHRA at GoodCOP 2.0?
CAPHRA plays a vital role in advocating for tobacco harm reduction, bringing attention to the importance of sensible regulatory policies, especially in Asia.
What does the white paper reveal?
The white paper highlights inconsistencies in WHO's tobacco control measures and argues for the recognition of harm reduction as a key component of these policies.
What recommendations does the white paper provide?
The paper recommends that WHO officially endorse harm reduction in its policies, promote stakeholder engagement, and ensure transparency in decision-making processes.
What are the risks of ignoring tobacco harm reduction?
Denying tobacco harm reduction can perpetuate preventable diseases, increase illicit trade, and erode trust in public health initiatives.
How can stakeholders engage in this discussion?
Stakeholders, including consumers and scientists, are encouraged to participate in discussions and advocate for policies that promote harm reduction practices.
